eMedicine Specialties > Pediatrics: General Medicine > Hematology

Pelger-Huet Anomaly: Differential Diagnoses & Workup

Author: Vikramjit S Kanwar, MD, MBA, MRCP(UK), FAAP, Associate Professor of Pediatric Hematology and Oncology, Department of Pediatrics, Albany Medical Center; Faculty, Alden March Bioethics Institute
Contributor Information and Disclosures

Updated: Mar 25, 2009

Differential Diagnoses

Enteroviral Infections
Malaria
Myelodysplasia
Myelodysplastic Syndrome
Panhypopituitarism

Other Problems to Be Considered

The practical importance of identifying Pelger-Huët anomaly (PHA) lies in distinguishing this defect from a bandemia with a left-shifted peripheral blood smear and neutrophilic band forms and from an increase in young neutrophilic forms that can be observed in association with infection.

Acquired or pseudo-PHA often develops in the course of acute or chronic myelogenous leukemia and in myelodysplastic syndromes. In patients with these conditions, the pseudo–Pelger-Huët cells tend to appear late in the disease and often appear after considerable chemotherapy has been administered. The morphologic changes have also been described in myxedema associated with panhypopituitarism, vitamin B-12 and folate deficiency, multiple myeloma, enteroviral infections, malaria, muscular dystrophy, leukemoid reactions secondary to metastases to the bone marrow, and drug sensitivity.

The acquired neutrophil nuclear changes observed in these conditions can be differentiated from the constitutional form as follows: Fewer bilobed cells and a higher percentage of normal trilobed neutrophils are present in patients with pseudo–PHA than in patients with the constitutional form of PHA, and leukemic and immature cells may be present.

Workup

Laboratory Studies

  • Examination of a peripheral blood smear in an individual heterozygous for Pelger-Huët anomaly (PHA) is remarkable for neutrophils with a predominance of bilobed, spectacle-shaped nuclei. This appearance is often described as pince-nez. Cells that contain twin, joined, and plump nuclei resembling dumbbells are predominant. A thin bridge, which is thinner than that observed in a normal band neutrophil, joins the 2 lobes. Although rare, homozygous individuals are described.
    • About 69-93% of the neutrophils show nuclear segmentation that is arrested at the bilobe level. A small population of neutrophils that possess a nonlobulated oblong or peanut-shaped nucleus is often present.
    • Less than 10% of cells contain 3 lobes; 4 lobes are rare.
    • Most neutrophils have excessively coarse clumping of the nuclear chromatin. The finding of similar abnormalities in the blood smear of other family members may help in establishing the diagnosis.
  • The homozygous state results in neutrophils that contain a single, round, eccentric nucleus with clumped chromatin and little or no nuclear segmentation. In contrast to the less than 40% of single-lobed neutrophils typically present in heterozygous individuals, most neutrophils in homozygous individuals are round or oval. In homozygous individuals, the basophils, eosinophils, and megakaryocytes also show dense nuclear chromatin and rounded nuclear lobes.
  • The bone marrow of homozygous patients reveals normal morphologic features in the myeloid precursors to the myelocyte stage.
  • Electron microscopy reveals persistence of nucleoli in the mature neutrophils that contain a single oval nucleus. This finding suggests altered and retarded nuclear maturation of the myeloid precursors.
  • When Pelger-Huët cells are identified, initially attempt to determine if the patient has a benign inherited anomaly, an acquired morphologic feature associated with a transient condition, or evolving myelodysplasia.
  • Acquired or pseudo-PHA cells may appear morphologically similar to those observed in the hereditary form; therefore, determining whether detailed workup is necessary may be difficult.
    • In the hereditary form of PHA, an autosomal dominant pattern should be present, and this finding in other family members may be helpful and reassuring.
    • In this condition, no other cell line should be involved. In contrast, if anemia or thrombocytopenia are observed, perform an evaluation to exclude a hematologic malignancy.
    • Pseudo-PHA cells may be predicative of the clinical onset of myelodysplastic disorders and malignant conditions, such as acute myelogenous leukemia, chronic myelogenous leukemia, or myelofibrosis. Therefore, if clinical suspicion warrants it, bone-marrow aspiration and biopsy are necessary.

More on Pelger-Huet Anomaly

Overview: Pelger-Huet Anomaly
Differential Diagnoses & Workup: Pelger-Huet Anomaly
Treatment & Medication: Pelger-Huet Anomaly
Follow-up: Pelger-Huet Anomaly
Multimedia: Pelger-Huet Anomaly
References

References

  1. Cohen TV, Klarmann KD, Sakchaisri K, et al. The lamin B receptor under transcriptional control of C/EBPepsilon is required for morphological but not functional maturation of neutrophils. Hum Mol Genet. Oct 1 2008;17(19):2921-33. [Medline].

  2. Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM. Historical perspective and clinical implications of the Pelger-Huet cell. Am J Hematol. Feb 2009;84(2):116-9. [Medline].

  3. Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet. Aug 2002;31(4):410-4. [Medline].

  4. Hoffmann K, Sperling K, Olins AL, Olins DE. The granulocyte nucleus and lamin B receptor: avoiding the ovoid. Chromosoma. Jun 2007;116(3):227-35. [Medline].

  5. Ye Q, Callebaut I, Pezhman A, Courvalin JC, Worman HJ. Domain-specific interactions of human HP1-type chromodomain proteins and inner nuclear membrane protein LBR. J Biol Chem. Jun 6 1997;272(23):14983-9. [Medline].

  6. Cohen TV, Klarmann KD, Sakchaisri K, Cooper JP, Kuhns D, Anver M, et al. The lamin B receptor under transcriptional control of C/EBPepsilon is required for morphological but not functional maturation of neutrophils. Hum Mol Genet. Oct 1 2008;17(19):2921-33. [Medline].

  7. Oosterwijk JC, Mansour S, van Noort G, et al. Congenital abnormalities reported in Pelger-Huët homozygosity as compared to Greenberg/HEM dysplasia: highly variable expression of allelic phenotypes. J Med Genet. Dec 2003;40(12):937-41. [Medline].

  8. Best S, Salvati F, Kallo J, et al. Lamin B-receptor mutations in Pelger-Huët anomaly. Br J Haematol. Nov 2003;123(3):542-4. [Medline].

  9. Erice JG, Perez JM, Pericas FS. Homozygous form of the Pelger-Huët anomaly. Haematologica. Aug 1999;84(8):748. [Medline].

  10. Jandl JH. Leukocyte anomalies. In: Blood: Textbook of Hematology. 2nd ed. Boston, Mass: Little, Brown; 1996:788.

  11. Kalfa TA, Zimmerman SA, Goodman BK, et al. Pelger-Huët anomaly in a child with 1q42.3-44 deletion. Pediatr Blood Cancer. May 1 2006;46(5):645-8. [Medline].

  12. Klein A, Hussar AE, Bornstein S. Pelger-Huët anomaly of the leukocytes. N Engl J Med. Dec 15 1955;253(24):1057-62. [Medline].

  13. Matsumoto T, Harada Y, Yamaguchi K, et al. Cytogenetic and functional studies of leukocytes with Pelger-Huët anomaly. Acta Haematol. 1984;72(4):264-73. [Medline].

Further Reading

Keywords

Pelger-Huet anomaly, Pelger-Huët anomaly, Pelger-Huët nuclear anomaly, Pelger-Huet nuclear anomaly, PHA, pelgerization, LBR gene, pseudo-PHA, acquired PHA, Pelger-Huët cells, Pelger-Huet cells, 1q42, myeloid leukemia, myelodysplasia, acute lymphocytic leukemia, hydrops, ectopic calcifications, moth-eaten dysplasia syndrome, Greenberg syndrome, HEM, developmental delay, seizures, skeletal anomalies, skeletal dysplasia

Contributor Information and Disclosures

Author

Vikramjit S Kanwar, MD, MBA, MRCP(UK), FAAP, Associate Professor of Pediatric Hematology and Oncology, Department of Pediatrics, Albany Medical Center; Faculty, Alden March Bioethics Institute
Vikramjit S Kanwar, MD, MBA, MRCP(UK), FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, and Royal College of Physicians of the United Kingdom
Disclosure: Nothing to disclose.

Medical Editor

Sharada A Sarnaik, MB, BS, Professor of Pediatrics, Wayne State University School of Medicine; Director, Sickle Cell Center, Attending Hematologist/Oncologist, Children's Hospital of Michigan
Sharada A Sarnaik, MB, BS is a member of the following medical societies: American Association of Blood Banks, American Association of University Professors, American Society of Hematology, American Society of Pediatric Hematology/Oncology, New York Academy of Sciences, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

James L Harper, MD, Associate Professor, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, Associate Chairman for Education, Department of Pediatrics, University of Nebraska Medical Center; Assistant Clinical Professor, Department of Pediatrics, Creighton University; Director, Continuing Medical Education, Children's Memorial Hospital; Pediatric Director, Nebraska Regional Hemophilia Treatment Center
James L Harper, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Federation for Clinical Research, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Council on Medical Student Education in Pediatrics, and Hemophilia and Thrombosis Research Society
Disclosure: Nothing to disclose.

CME Editor

Samuel Gross, MD, Professor Emeritus, Department of Pediatrics, University of Florida; Clinical Professor, Department of Pediatrics, University of North Carolina; Adjunct Professor, Department of Pediatrics, Duke University
Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD, King Fahd Professor of Pediatric Oncology, Department of Oncology, Division of Pediatric Oncology, Johns Hopkins University School of Medicine
Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.